USRE31429E - Process for preparation of 9-(dihalobenzyl)adenines - Google Patents

Process for preparation of 9-(dihalobenzyl)adenines Download PDF

Info

Publication number
USRE31429E
USRE31429E US06/087,603 US8760379A USRE31429E US RE31429 E USRE31429 E US RE31429E US 8760379 A US8760379 A US 8760379A US RE31429 E USRE31429 E US RE31429E
Authority
US
United States
Prior art keywords
dihalobenzyl
preparation
adenines
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/087,603
Inventor
Robert Tull, deceased
George D. Hartman
Leonard M. Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/768,235 external-priority patent/US4098787A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US06/087,603 priority Critical patent/USRE31429E/en
Application granted granted Critical
Publication of USRE31429E publication Critical patent/USRE31429E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Definitions

  • This invention relates to a novel process for preparing 9-(2,6-dihalobenzyl)adenines.
  • Said purines are described in U.S. Pat. No. 3,846,426 as being useful in the treatment and prevention of coccidoisis.
  • Coccidiosis is a widespread poultry disease which is produced by infections of protozoa of the genus Eimeria which causes severe pathology in the intestines and ceca of poultry. Some of the most significant of these species are E. tenella, E. acervulina, E. necatrix, E. brunetti and E. maxima. This disease is generally spread by the birds picking up the infectious organism in droppings on contaminated litter or ground, or by way of food drinking water. The disease is manifested by hemorrhage, accumulation of blood in the ceca, passage of blood in the droppings, weakness and digestive disturbances. The disease often terminates in the death of the animal, but the fowl which survive severe infections have had their market value substantially reduced as a result of the infection. Coccidiosis is, therefore, a disease of great economic importance and extensive work has been done to find new and improved methods for controlling and treating coccidial infections in poultry.
  • 9-(dihalobenzyl)adenines have been prepared by alkylating adenine with dihalobenzyl halides. This process suffers from the disadvantage that alkylation is not selective and substitution occurs to some extent at the 3-position and other positions of adenine.
  • 9-substituted adenines (2) may be prepared via reductive cleavage and subsequent cyclization of 7-amidofurazano[3,4-d]pyrimidines (1).
  • adenine derivatives was prepared, the authors were unable to effect the conversion of 5-unsubstituted 7-amidofurazano[3,4-d]pyrimidines (1, R ⁇ H, Y ⁇ O) to 2-unsubstituted adenines (2, R ⁇ H) due to the hydrolytic instability of the former compounds.
  • 9-(dihalobenzyl)adenines unsubstituted at the 2-position, are prepared without isomer contamination according to the process set forth in Table I.
  • X 1 and X 2 are independently halogen.
  • 4,5,6-Triaminopyrimidine (3) obtained by the process set forth in A. Shrage et al., J. Org. Chem., 16, 207 (1951), with thionyl chloride affords 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine (4).
  • Nucleophilic displacement of the 7-amino group of (4) by the process of Y. F. Shealy et al., J. Org. Chem., 27, 2135 (1964), at 100° C. with 2,6-dihalobenzylamine (5) provides (6).
  • (6) can be prepared from (4) by treatment of (4) with ammonia and 2,6-dihalobenzyl chloride in a sealed vessel at 100° C.
  • Formylation of (6) at room temperature with formic acetic anhydride yields (7) as a stable solid.
  • Treatment of a solution of (7) with Raney nickel results in smooth desulfurization and formation of (9).
  • the desulfurization may be carried out in an aqueous alcohol solvent wherein the alcohol preferably contains 1 to 6 carbon atoms.
  • the reaction may be conducted at a temperature range of about room temperature to about 125° C. for a period of about 1 hour to 24 hours. Preferred conditions are ethanol-water at about room temperature for about 2 hours.
  • the present process may be extended to prepare adenine derivatives having the following structure: ##STR8## wherein R and R' are independently H, alkyl, aryl or substituted aryl; and R" is alkyl or substituted benzyl.
  • the substituents are those stable to Raney nickel reduction.
  • Formic acetic anhydride was prepared by stirring for 1 hour at 0°-5° C. a solution of 18.4 g. (0.4 mole) of 98% formic acid and 40.8 g. (0.4 mole) acetic anhydride. Forty ml. of this solution was added to 2.0 g. (0.0067 mole) of 7-(2-chloro-6-fluorobenzylamino) [1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 3, and the solution stirred overnight. Any insoluble material was filtered off and the filtrate concentrated in vacuo at 50° C. The solid residue was washed with ether and recrystallized from methanol to afford 2.0 g. (91%) of the desired compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

9-(Dihalobenzyl)adenines are prepared uncontaminated with other positional isomers in a series of mild transformations starting from 4,5,6-triaminopyrimidine and proceeding via 7-(N-formyl-N-dihalobenzyl)amino[1,2,5]-thiadiazolo[3,4-d]pyrimidine. The resulting compounds have anticoccidial activity and are useful in controlling cecal and/or intestinal coccidiosis when administered in minor quantities to animals, in particular to poultry usually in admixture with animal sustenance.

Description

BACKGROUND OF THE INVENTION
This invention relates to a novel process for preparing 9-(2,6-dihalobenzyl)adenines. Said purines are described in U.S. Pat. No. 3,846,426 as being useful in the treatment and prevention of coccidoisis.
Coccidiosis is a widespread poultry disease which is produced by infections of protozoa of the genus Eimeria which causes severe pathology in the intestines and ceca of poultry. Some of the most significant of these species are E. tenella, E. acervulina, E. necatrix, E. brunetti and E. maxima. This disease is generally spread by the birds picking up the infectious organism in droppings on contaminated litter or ground, or by way of food drinking water. The disease is manifested by hemorrhage, accumulation of blood in the ceca, passage of blood in the droppings, weakness and digestive disturbances. The disease often terminates in the death of the animal, but the fowl which survive severe infections have had their market value substantially reduced as a result of the infection. Coccidiosis is, therefore, a disease of great economic importance and extensive work has been done to find new and improved methods for controlling and treating coccidial infections in poultry.
9-(dihalobenzyl)adenines have been prepared by alkylating adenine with dihalobenzyl halides. This process suffers from the disadvantage that alkylation is not selective and substitution occurs to some extent at the 3-position and other positions of adenine.
E. C. Taylor, et al., J. Org. Chem. 36, 3211 (1971) have reported that 9-substituted adenines (2) may be prepared via reductive cleavage and subsequent cyclization of 7-amidofurazano[3,4-d]pyrimidines (1). ##STR1## Although a wide variety of adenine derivatives was prepared, the authors were unable to effect the conversion of 5-unsubstituted 7-amidofurazano[3,4-d]pyrimidines (1, R═H, Y═O) to 2-unsubstituted adenines (2, R═H) due to the hydrolytic instability of the former compounds.
According to the process of the present invention this conversion has been successfully performed in the case wherein in compound (1) R═H, Y═S and R'═ dihalobenzyl to provide 9-(dihalobenzyl)adenines (2) wherein R═H and R'═ dihalobenzyl uncontaminated with positional isomers.
SUMMARY OF THE INVENTION
According to the process of the present invention 9-(dihalobenzyl)adenines, unsubstituted at the 2-position, are prepared without isomer contamination according to the process set forth in Table I.
              TABLE I                                                     
______________________________________                                    
 ##STR2##                                                                 
 ##STR3##                                                                 
 ##STR4##                                                                 
 ##STR5##                                                                 
 ##STR6##                                                                 
 ##STR7##                                                                 
______________________________________                                    
wherein X1 and X2 are independently halogen.
4,5,6-Triaminopyrimidine (3), obtained by the process set forth in A. Shrage et al., J. Org. Chem., 16, 207 (1951), with thionyl chloride affords 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine (4). Nucleophilic displacement of the 7-amino group of (4) by the process of Y. F. Shealy et al., J. Org. Chem., 27, 2135 (1964), at 100° C. with 2,6-dihalobenzylamine (5) provides (6). Alternatively, (6) can be prepared from (4) by treatment of (4) with ammonia and 2,6-dihalobenzyl chloride in a sealed vessel at 100° C. Formylation of (6) at room temperature with formic acetic anhydride yields (7) as a stable solid. Treatment of a solution of (7) with Raney nickel results in smooth desulfurization and formation of (9). The desulfurization may be carried out in an aqueous alcohol solvent wherein the alcohol preferably contains 1 to 6 carbon atoms. The reaction may be conducted at a temperature range of about room temperature to about 125° C. for a period of about 1 hour to 24 hours. Preferred conditions are ethanol-water at about room temperature for about 2 hours.
The present process may be extended to prepare adenine derivatives having the following structure: ##STR8## wherein R and R' are independently H, alkyl, aryl or substituted aryl; and R" is alkyl or substituted benzyl. The substituents are those stable to Raney nickel reduction.
Included within the scope of the present invention are the intermediates useful for the preparation of anticoccidial agents having the structural formula: ##STR9## wherein X1 and X2 are independently halogen and R'" is H or CHO.
The following non-limiting Examples will serve to further illustrate the instant invention.
EXAMPLE 1 Preparation of 7-Amino[1,2,5]thiadiazolo[3,4-d]pyrimidine
A flask was charged with 19.78 g. (0.15 mole) of 4,5,6-triaminopyrimidine and 163.0 g. (137 mole) of thionyl chloride and the mixture stirred at reflux for 18 hours. The dark orange reaction mixture was evaporated to dryness on the rotary evaporator and to the residue was added 500 ml. water and 40 ml. methanol. The resulting solution was adjusted to a pH of 7.5-8.0 with saturated sodium bicarbonate solution and heated to reflux. The hot mixture was filtered and the filtrate cooled to 0°-5° C. in an ice-bath. The solid was collected by filtration, washed twice with 50 ml. ice water and twice with 50 ml. ether. The resulting tan product was dried in vacuo at 70° C. overnight to afford 18.2 g. (79%) of product. M.p. 247°-249° C.; tlc on silica gel in chloroform-methanol (8:1) showed one spot at Rf ═0.4.
EXAMPLE 2 Preparation of 2-Chloro-6-fluorobenzylamine
An autoclave was charged with 89.0 g. (0.5 mole) of 2-chloro-6-fluorobenzyl chloride, 170.0 g. (10 mole) ammonia and 50 ml. benzene. The reaction vessel was sealed and the contents heated at 100° C. for 15 hours. The excess ammonia was carefully evaporated off from the cooled contents of the autoclave with a stream of nitrogen. The residue was washed with water, and the organic phase after drying with anhydrous MgSO4, fractionated to afford 72.4 g. (90%) of product as a clear liquid; b.p. 99°-100° C./20 mm; NMR (CDCl3) δ 1.46 (s, 2H); 3.88 (d, 2H); 7.00 (m, 3H).
EXAMPLE 3 Preparation of 7-(2-Chloro-6-fluorobenzylamino)[1,2,5]thiadiazolo[3,4-d]pyrimidine
A flask was charged with 1.54 g. (0.01 mole) of 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 1 and 4.0 g. (0.025 mole) of 2-chloro-6-fluorobenzylamine prepared by the process set forth in Example 2. The suspension was stirred and heated at 105° C. for 18 hours. Ten ml. water and 20 ml. hexane were added in one portion and the resulting solid collected by filtration. The cake was washed with hexane and dried at 50° C. in vacuo to afford 2.86 g. (97%) of product. M.p. 224°-226° C.; tlc on silica gel in chloroform-methanol (8:1) showed a single fluorescent blue spot at Rf ═0.8; NMR (DMSO-d6) δ 4.92 (2H, s); 7.21 (broad s, 3H); 8.44 (s, 1H); 9.45 (s, 1H).
Elemental analysis calculated for C11 H7 ClFN5 S: Calculated: C, 44.68; H, 2.38; N, 23.68. Found: C, 44.36; H, 2.38; N, 24.24.
EXAMPLE 4 Preparation of 7-(2-Chloro-6-fluorobenzylamino)[1,2,5]thiadiazolo[3,4,-d]pyrimidine
An autoclave was charged with 1.54 g. (0.01 mole) of 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 1, 5.1 g. (0.3 mole) ammonia and 4.48 g. (0.025 mole) 2-chloro-6-fluorobenzyl chloride. The vessel was sealed and the contents heated at 110° C. for 15 hours. After cooling and evaporation of the excess ammonia, the resulting solid was collected by filtration, washed successively with water and hexane to afford a 25% yield of product.
EXAMPLE 5 Preparation of 7-(N-formyl-N-2-chloro-6-fluorobenzyl)amino[1,2,5]thiadiazolo[3,4-d]pyrimidine
Formic acetic anhydride was prepared by stirring for 1 hour at 0°-5° C. a solution of 18.4 g. (0.4 mole) of 98% formic acid and 40.8 g. (0.4 mole) acetic anhydride. Forty ml. of this solution was added to 2.0 g. (0.0067 mole) of 7-(2-chloro-6-fluorobenzylamino) [1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 3, and the solution stirred overnight. Any insoluble material was filtered off and the filtrate concentrated in vacuo at 50° C. The solid residue was washed with ether and recrystallized from methanol to afford 2.0 g. (91%) of the desired compound. M.p. 133°-135° C.; tlc on silica gel in chloroform-methanol (16:1) showed one spot with Rf ═0.8; ir(CHCl3) 1730, 1540, 1120, 940 cm-1 ; NMR (DMSO-d6) δ 5.55 (s, 2H); 7.30 (broad s, 3H); 911 (s, 1H); 1033 (s, 1H).
EXAMPLE 6 Preparation of 9-(2-Chloro-6-fluorobenzyl)adenine
A flask was charged with 0.5 g. (0.0016 mole) of 7-(N-formyl-N-2-chloro-6-fluorobenzyl)amino[1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 5, 15 ml. ethanol, 15 ml. water and 7.0 g. of Raney nickel. The dark suspension was stirred at room temperature for 2 hours at which time tlc analysis showed the reaction to be complete. The reaction mixture was filtered through celite and the cake was washed with 200 ml. of boiling methanol. The clear filtrate was concentrated in vacuo to afford a while solid residue which was recrystallized from methanol-water to afford 0.18 g. (40%) of product. M.p. 245°-246° C.; tlc on silica gel in chloroform-methanol (16:1) showed one spot with Rf ═0.4; NMR (acetic acid-d4) δ 5.70 (2H, d); 7.35 (3H, m); 8.15 (1H, s).
Elemental analysis calculated for C12 H9 ClFN5 : Calculated: C, 51.90; H, 3.27; N, 25.22; Cl, 12.77. Found: C, 51.77; H, 3.30; N, 25.43; Cl, 12.49.

Claims (2)

What is claimed is:
1. The process for the preparation of compounds having the structure: ##STR10## wherein X1 and X2 are independently halogen by reacting the compound having the structure: ##STR11## wherein X1 and X2 are as defined above with Raney nickel in aqueous-alcohol solvent at about room temperature to about 125° C. for a period of about 1 hour to 24 hours. .Iadd.
2. The compound 9-(2-chloro-6-fluorobenzyl)adenine free of 3-position isomers such that said compound has a melting point of 245°-246° C.; a thin layer chromatogram on silica gel in chloroform-methanol (16:1) showing one spot with an Rf of 0.4; and a nuclear magnetic resonance spectrum in acetic acid-d4 of δ 5.70 (2 hydrogens-doublet), δ 7.35 (3 hydrogens-multiplet, and δ 8.15 (1 hydrogen-singlet)..Iaddend.
US06/087,603 1977-02-14 1979-10-23 Process for preparation of 9-(dihalobenzyl)adenines Expired - Lifetime USRE31429E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US06/087,603 USRE31429E (en) 1977-02-14 1979-10-23 Process for preparation of 9-(dihalobenzyl)adenines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/768,235 US4098787A (en) 1977-02-14 1977-02-14 Process for preparation of 9-(dihalobenzyl) adenines
US06/087,603 USRE31429E (en) 1977-02-14 1979-10-23 Process for preparation of 9-(dihalobenzyl)adenines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05/768,235 Reissue US4098787A (en) 1977-02-07 1977-02-14 Process for preparation of 9-(dihalobenzyl) adenines

Publications (1)

Publication Number Publication Date
USRE31429E true USRE31429E (en) 1983-10-25

Family

ID=26777171

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/087,603 Expired - Lifetime USRE31429E (en) 1977-02-14 1979-10-23 Process for preparation of 9-(dihalobenzyl)adenines

Country Status (1)

Country Link
US (1) USRE31429E (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110818A (en) * 1988-10-06 1992-05-05 Ciba-Geigy Corporation Anticonvulsive substituted-9-benzyl-9h-purines
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5889014A (en) * 1994-10-12 1999-03-30 Euro-Celtique, S.A. Heterocyclic compounds for inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5939422A (en) 1993-06-22 1999-08-17 Euro-Celtique, S.A. Chemical compounds having PDE-IV inhibition activity
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6228859B1 (en) 1997-12-12 2001-05-08 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US6413975B1 (en) 1999-04-02 2002-07-02 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase iv inhibition activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813394A (en) * 1969-08-18 1974-05-28 Fujisawa Pharmaceutical Co Purine derivatives having hypocholesterolemic activity
US3846426A (en) * 1971-03-03 1974-11-05 Int Minerals & Chem Corp 6-amino-9-(substituted benzyl) purines and their n{11 oxides
US4100159A (en) * 1977-02-07 1978-07-11 Merck & Co., Inc. Process for preparation of 9-(2,6-dihalobenzyl)adenines
US4171440A (en) * 1977-10-20 1979-10-16 Merck & Co., Inc. Process for purification of 9-(2,6-dihalobenzyl)adenines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813394A (en) * 1969-08-18 1974-05-28 Fujisawa Pharmaceutical Co Purine derivatives having hypocholesterolemic activity
US3846426A (en) * 1971-03-03 1974-11-05 Int Minerals & Chem Corp 6-amino-9-(substituted benzyl) purines and their n{11 oxides
US4100159A (en) * 1977-02-07 1978-07-11 Merck & Co., Inc. Process for preparation of 9-(2,6-dihalobenzyl)adenines
US4171440A (en) * 1977-10-20 1979-10-16 Merck & Co., Inc. Process for purification of 9-(2,6-dihalobenzyl)adenines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hallstein et al. (Mutation Research 65 133-142 (1979). *
Purchase et al. (British Journal of Cancer 37 873-903 (1978). *
Shealey et al., J. Org. Chem., 27 2154-2160, (1962). *
Taylor et al., J. Chem. Soc., 36 3211-3217, (1971). *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110818A (en) * 1988-10-06 1992-05-05 Ciba-Geigy Corporation Anticonvulsive substituted-9-benzyl-9h-purines
US5939422A (en) 1993-06-22 1999-08-17 Euro-Celtique, S.A. Chemical compounds having PDE-IV inhibition activity
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5889014A (en) * 1994-10-12 1999-03-30 Euro-Celtique, S.A. Heterocyclic compounds for inhibiting phosphodiesterase IV
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US6310205B1 (en) 1996-06-06 2001-10-30 Euro-Celtique, S.A. Hypoxathine compounds
US6228859B1 (en) 1997-12-12 2001-05-08 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US6413975B1 (en) 1999-04-02 2002-07-02 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase iv inhibition activity

Similar Documents

Publication Publication Date Title
KR100242580B1 (en) Process for the preparation of pyrimidine compounds
US5017701A (en) Process for the preparation of purine derivatives
USRE31429E (en) Process for preparation of 9-(dihalobenzyl)adenines
US4361699A (en) Novel process for the preparation of N6 -alkyl-arprinocid
JPH0725761B2 (en) 4 (3H) -Pteridinones, Production Method Thereof, Antiallergic Agent, and Bronchoconstrictor Preventive Agent
KR930005175B1 (en) Process for preparing 4,7-dihydro thieno |2,3-b¨ pyridine derivative
SK14672001A3 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
KR910005850B1 (en) Process for the preparation of imidazo (1,5-a) pyrimidien derivatives
US4098787A (en) Process for preparation of 9-(dihalobenzyl) adenines
CZ20022178A3 (en) Process for preparing pyrazolo pyridazine derivatives
HU196188B (en) Process for preparing new quinazolindione-derivatives and medical compounds containing them
US5006656A (en) Preparation of 5,7-dihydroxy-1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonanilides
JPS634544B2 (en)
HU185329B (en) Process for preparing quinolone derivatives and pharmaceutical compositions containing such compounds
US4575553A (en) Antitumor m-AMSA analog
KR100233068B1 (en) Process for the preparation of 2-substituted 4,6-dialkoxypyrimidine
US4086348A (en) Naphthyridine derivatives
EP0110496B1 (en) Improvements in keto intermediates, their use and preparation
US4286093A (en) 9-Cyclohexyl-2-alkoxy-9H-adenine process
EP0564006A2 (en) Process for preparing purine derivatives and novel purine derivatives
US2807616A (en) Oxazolopyrimidines and method of preparing same
CS261250B2 (en) Method of 1-methylaminoquinolinecarboxyl acid's and its derivatives production
US5703233A (en) Quinilone disulfide as intermediates
US5278307A (en) Process for preparing 4-hydroxypyrrolo(2,3-d)pyrimidine based antifolate compounds and intermediates
US4568744A (en) Benzylpyrimidine synthesis and intermediates